Saúde Pública®Edições Especiais Saúde Pública®Mundo Médico®Edições especiais Mundo Médico®Mundo Farmacêutico®Informação SIDA®HematOncologia®Jornal Pré-CongressoJornal do CongressoJornal Diário do CongressoSaúde em Dia®Outros Projectos
Notícia
Renal Cell Carcinoma [RCC] – Where do we stand in 2010?
O Instituto de Educação Médica organiza, dias 19 e 20 de Fevereiro de 2010, no Auditório Agostinho da Silva da Universidade Lusófona de Humanidades e Tecnologias, em Lisboa, o «Renal Cell Carcinoma [RCC] – Where do we stand in 2010?».
Scientific Sponsors:
Associação Portuguesa de Urologia
Sociedade Portuguesa de Oncologia Médica
Colégio da Especialidade de Urologia da Ordem dos Médicos
Colégio da Especialidade de Oncologia Médica da Ordem dos Médicos
Welcome Address
- Alberto Matos-Ferreira
14.45 - 15.00 Introduction to the Course
- Arnaldo Figueiredo
- Carlos Carvalho
Session 1
Nomenclature, Incidence, Etiopathogenesis, Pathophysiology, Histology and Stages
CHAIRS:
- Carlos Carvalho
- José Manuel Palma dos Reis
15.00 - 15.40
1. RCC: a disease of our time
Incidence, trends in recent decades, impact in terms of mortality an morbidity
- João Bastos
2. What diseases predispose individuals to RCC?
What do we know about genetic and environmental
causes of RCC?
- José Miguel Leal de Carvalho
15.40 - 16.00
3. What are the mechanisms and most common sites of metastases?
What are the signs and symptoms of the primary tumor, metastatic disease and paraneoplastic syndromes?
- Manuel Ferreira Coelho
16.00 - 16.30 Break
16.30 - 16.50
4. What laboratory exams are important in a work-up for RCC?
Carlos M. Silva
16.50 - 17.20
5. Histological features and stages of RCC and their significance in defining each type of RCC
- Pedro Oliveira
17.20 - 17.40
6. How is the differential diagnosis of RCC made?
José Manuel Palma dos Reis
17.40 - 18.20
7. Which imaging studies should be done to detectM RCC?
Guida Matos-Ferreira
8. Which imaging studies make it possible to precisely
identify the characteristics and stage of RCC?
João Castaño
9. What role do isotope studies and PET scans play in evaluating cases of RCC?
Lucília Salgado
18.20 - 18.50
Round Table 1
Nomenclature, Incidence, Etiopathogenesis, Pathophysiology, Histology and Stages
CHAIRS
- Chairs and speakers from Session 1
18.50 - 19.50 Poster Session
CHAIRS
- João Pádua Marcelino
- João Marcelino
- Belmiro Parada
19.50 Closing of the Session
Localized, Locally Advanced and Disseminated Carcinoma.
Treatment, Prognosis and Economic Considerations
CHAIRS
- Hendrik van Popel
- Arnaldo Figueiredo
09.00 - 09.40
10. The treatment strategy of advanced RCC
– Clinical trials and clinical relevance.
- Carlos Carvalho
11. What hope do new therapies bring to the treatment of RCC?
- Hendrik van Popel
09.40 - 10.20
12. What type of surgical therapy should I choose?
A – Which approach? Open, laparoscopic or robotic
surgery?
- Jean de la Rosette
B – Which technique? Radical nephrectomy, partial
nephrectomy or tumorectomy?
How important are the margins to the results of surgical therapy?
Arnaldo Figueiredo
10.20 - 11.00
13. What is the role of cryoablation, radiofrequency ablation, HIFU and embolization in the treatment of RCC?
- Pilar Laguna
- Luís Campos Pinheiro
- João Martins Pisco
11.00 - 11.15
14. What follow-up should patients who have been treated for RCC have?
- João P. Varregoso
11.15 - 11.30
15. What combination therapies can be used in RCC, and what are the indications for nephrectomy in metastatic disease?
- Fernando Calais da Silva
11.30 - 11.45
16. In cases where renal masses are suspicious for RCC, is watchful waiting an acceptable option?
- José Santos Dias
11.45 - 12.00
17. How is the prognosis for patients with RCC determined?
What is the role of prognostic nomograms?
- Pedro Nunes
12.00 - 12.30 Break
12.30 - 12.45
18. In which situations is palliative therapy used?
- Isabel Galriça Neto
12.45 - 13.00
19. Economic considerations in the treatment of RCC. Cost-benefit analysis. Third-party copayment of therapy.
- Tomé Lopes
13.00 - 13.30
Round Table 2
Localized, Locally Advanced and Disseminated Carcinoma.
Treatment, Prognosis and Economic Considerations
CHAIRS
- Chairs and speakers from Session 2
13.30 - 13.45
20. What important points and messages we can take away from this course?
Arnaldo Figueiredo
13.45 Closing remarks
- Alberto Matos-Ferreira
SECRETARIAT:
Instituto de Educação Médica
Faculdade de Ciências Médicas
da Universidade Lusófona de Humanidades e Tecnologias
c/o Angela M. Vasconcelos
Campo Grande, 376
1749-024 LISBOA
Tel: +351 218 853 079 | +351 962184972
Fax: +351 218 853 464
Email: iem@iem.pt
www.iem.pt
Scientific Sponsors:
Associação Portuguesa de Urologia
Sociedade Portuguesa de Oncologia Médica
Colégio da Especialidade de Urologia da Ordem dos Médicos
Colégio da Especialidade de Oncologia Médica da Ordem dos Médicos
Programme:
All sessions will be conducted in English
Feb. 19 [Friday]
Welcome Address
- Alberto Matos-Ferreira
14.45 - 15.00 Introduction to the Course
- Arnaldo Figueiredo
- Carlos Carvalho
Session 1
Nomenclature, Incidence, Etiopathogenesis, Pathophysiology, Histology and Stages
CHAIRS:
- Carlos Carvalho
- José Manuel Palma dos Reis
15.00 - 15.40
1. RCC: a disease of our time
Incidence, trends in recent decades, impact in terms of mortality an morbidity
- João Bastos
2. What diseases predispose individuals to RCC?
What do we know about genetic and environmental
causes of RCC?
- José Miguel Leal de Carvalho
15.40 - 16.00
3. What are the mechanisms and most common sites of metastases?
What are the signs and symptoms of the primary tumor, metastatic disease and paraneoplastic syndromes?
- Manuel Ferreira Coelho
16.00 - 16.30 Break
16.30 - 16.50
4. What laboratory exams are important in a work-up for RCC?
Carlos M. Silva
16.50 - 17.20
5. Histological features and stages of RCC and their significance in defining each type of RCC
- Pedro Oliveira
17.20 - 17.40
6. How is the differential diagnosis of RCC made?
José Manuel Palma dos Reis
17.40 - 18.20
7. Which imaging studies should be done to detectM RCC?
Guida Matos-Ferreira
8. Which imaging studies make it possible to precisely
identify the characteristics and stage of RCC?
João Castaño
9. What role do isotope studies and PET scans play in evaluating cases of RCC?
Lucília Salgado
18.20 - 18.50
Round Table 1
Nomenclature, Incidence, Etiopathogenesis, Pathophysiology, Histology and Stages
CHAIRS
- Chairs and speakers from Session 1
18.50 - 19.50 Poster Session
CHAIRS
- João Pádua Marcelino
- João Marcelino
- Belmiro Parada
19.50 Closing of the Session
Feb. 20 [Saturday]
Session 2Localized, Locally Advanced and Disseminated Carcinoma.
Treatment, Prognosis and Economic Considerations
CHAIRS
- Hendrik van Popel
- Arnaldo Figueiredo
09.00 - 09.40
10. The treatment strategy of advanced RCC
– Clinical trials and clinical relevance.
- Carlos Carvalho
11. What hope do new therapies bring to the treatment of RCC?
- Hendrik van Popel
09.40 - 10.20
12. What type of surgical therapy should I choose?
A – Which approach? Open, laparoscopic or robotic
surgery?
- Jean de la Rosette
B – Which technique? Radical nephrectomy, partial
nephrectomy or tumorectomy?
How important are the margins to the results of surgical therapy?
Arnaldo Figueiredo
10.20 - 11.00
13. What is the role of cryoablation, radiofrequency ablation, HIFU and embolization in the treatment of RCC?
- Pilar Laguna
- Luís Campos Pinheiro
- João Martins Pisco
11.00 - 11.15
14. What follow-up should patients who have been treated for RCC have?
- João P. Varregoso
11.15 - 11.30
15. What combination therapies can be used in RCC, and what are the indications for nephrectomy in metastatic disease?
- Fernando Calais da Silva
11.30 - 11.45
16. In cases where renal masses are suspicious for RCC, is watchful waiting an acceptable option?
- José Santos Dias
11.45 - 12.00
17. How is the prognosis for patients with RCC determined?
What is the role of prognostic nomograms?
- Pedro Nunes
12.00 - 12.30 Break
12.30 - 12.45
18. In which situations is palliative therapy used?
- Isabel Galriça Neto
12.45 - 13.00
19. Economic considerations in the treatment of RCC. Cost-benefit analysis. Third-party copayment of therapy.
- Tomé Lopes
13.00 - 13.30
Round Table 2
Localized, Locally Advanced and Disseminated Carcinoma.
Treatment, Prognosis and Economic Considerations
CHAIRS
- Chairs and speakers from Session 2
13.30 - 13.45
20. What important points and messages we can take away from this course?
Arnaldo Figueiredo
13.45 Closing remarks
- Alberto Matos-Ferreira
SECRETARIAT:
Instituto de Educação Médica
Faculdade de Ciências Médicas
da Universidade Lusófona de Humanidades e Tecnologias
c/o Angela M. Vasconcelos
Campo Grande, 376
1749-024 LISBOA
Tel: +351 218 853 079 | +351 962184972
Fax: +351 218 853 464
Email: iem@iem.pt
www.iem.pt
Copyright © 2006 JAS Farma®
Pretendemos promover e divulgar a informação na área da Saúde. A reprodução total ou parcial dos textos e fotografias é possível, desde que referenciada a sua origem (JAS Farma®) e com a autorização expressa da Direcção.